Bellevue Asset Management has hired a prominent new adviser for the Pureos Fund, which invests in the development of innovative drugs. He has a past as a top researcher at Swiss drugs giant Roche.
Omar Khwaja has joined the advisory board of BB Pureos Bioventures, the company said in a statement on Monday. The fund, which is part of Bellevue Asset Management, is an investment vehicle that specializes in innovative drugs.
Khwaja is an expert in neurosciences and neurogenetics. The physician is chief medical officer and head of research at Voyager Therapeutics, a biotech firm based in Boston.
His Past With Roche
Before joining Voyager Therapeutics, Khwaja worked for Swiss drugs giant Roche, where he held the roles of Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases. He led the first clinical programs in gene therapy during his time at Roche.
Before he joined the private sector drugs industry, Khwaja was director at Boston Children’s Hospital and at the faculty of Harvard Medical School.
